OsteoBiol GTO Syringe 0.5CC Tecnoss

Mix of collagenated heterologous cortical-spongious bone + TSV Gel TECNOSS®: A UNIQUE BIOTECHNOLOGY THAT PROMOTES AND GUIDES NATURAL BONE REGENERATION

Tecnoss® has developed and patented a unique biotechnology that prevents the ceramization phase of heterologous bone and preserves tissue collagen, allowing for osteoclastic remodeling of the biomaterial similar to physiological bone turnover and a product with characteristics very similar to those of human bone. The combination of these factors allows for significant bone neoformation and intimate contact between the newly formed bone and the biomaterial granules.

COLLAGEN: A KEY FACTOR FOR BONE REGENERATION

Collagen plays a fundamental role in bone regeneration because: a) it acts as a suitable substrate for platelet activation and aggregation; b) it is able to attract and stimulate the differentiation of mesenchymal stem cells present in bone marrow into osteoblasts; c) it increases the differentiation rate and activity of osteoblasts compared to bone marrow cells cultured on conventional culture capsules (5); d) it stimulates the activation of platelets, osteoblasts, and osteoclasts in the tissue healing process; e) it promotes the formation of new blood vessels and consequently the vascularization of the graft.

OSTEOBIOL® DUAL-PHASE BONE MATRIX + TSV GEL: A UNIQUE COMBINATION FOR GRAFT STABILIZATION

Thanks to its innovative composition, OsteoBiol® TSV Gel can provide mechanical stability to the OsteoBiol® GTO® granules during the grafting procedure. OsteoBiol® TSV Gel is then rapidly resorbed and does not influence the natural regenerative process underway. At room and body temperature, OsteoBiol® TSV Gel has a gel-like consistency: it never hardens and maintains a plasticity that allows a stable and cohesive mixture with the OsteoBiol® GTO® granules.

CHARACTERISTICS

OsteoBiol® GTO® is a bone substitute of porcine origin. It is a mix of collagenated cortico-spongious granules with a particle size of 600-1000 µm, appropriately mixed with OsteoBiol® TSV Gel, which is in turn a mixture of homologous type I and III collagen gel with polyunsaturated fatty acids diluted in an aqueous solution containing a biocompatible synthetic copolymer. OsteoBiol® GTO® is gradually resorbed and is extremely osteoconductive. Furthermore, the preserved collagen in the matrix facilitates clotting and subsequent invasion of regenerative cells. These unique characteristics allow for a high percentage of newly formed bone, excellent preservation of graft volume, healthy regenerated bone tissue, and ultimately successful implant rehabilitation.

USAGE

Available in two sizes (0.5 and 2.0 cc), OsteoBiol® GTO® is a pre-hydrated biomaterial ready for use and can be easily grafted into the bone defect by injecting it directly from the sterile syringe. This allows the clinician to avoid the preparation and hydration phase with physiological solution or blood, reducing time and the risk of exposure. OsteoBiol® GTO® shaped and ready to be grafted into the bone defect. Source: Dr. Patrick Palacci, Marseille, France. The presence of OsteoBiol® TSV Gel ensures optimal adhesion of the material, which remains easily adaptable to the recipient site and extremely stable.

CLINICAL INDICATIONS

OsteoBiol® GTO® is designed as a universal biomaterial, easily adaptable to any type of bone defect, to be used in association with OsteoBiol® Evolution membranes or the OsteoBiol® Lamina to protect the graft. However, thanks to its adhesiveness, it is particularly suitable for horizontal regeneration procedures (e.g., two-wall defects, when the ridge is very atrophic) and for socket preservation in cases of compromised vestibular cortical bone. During sinus lift with lateral access, OsteoBiol® GTO® can be applied directly through the antrostomy, helping to stabilize implants in one-stage surgery. OsteoBiol® GTO® can also be successfully used to treat peri-implant lesions and severe infraosseous defects.

Tecnoss srl is an innovative, globally active company dedicated to the development, production, and scientific documentation of high-quality xenogenic biomaterials marketed worldwide under the Tecnoss® and OsteoBiol® brands. With over 20 years of experience in research, the company utilizes a proprietary and patented process that guarantees both the neutralization of antigenic components and the resulting achievement of biocompatibility, as well as the preservation of the natural collagen matrix within the biomaterial. Tecnoss® products meet the highest quality standards, including ISO10993, ISO13485, and 93/42/EC.